文献类型：期刊文献

英文题名：Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions

作者：Xiang, Lanlan[1];Wang, Hao[1];Liu, Jiajie[1];Shen, Yuchen[2];Hu, Yanfen[1];Che, Wenchen[1];Li, Ran[1];Yang, Sisi[1];Teng, Xin[1]

机构：[1]East China Univ Sci & Technol, Natl Mat Expt Teaching Demonstrat Ctr, 130 Meilong Rd, Shanghai 200237, Peoples R China;[2]Univ New South Wales, Fac Biomed Engn, Sydney, NSW 2052, Australia

年份：2025

卷号：17

期号：2

外文期刊名：PHARMACEUTICS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001429785100001)】；

语种：英文

外文关键词：docetaxel; nanomicelles; allergic reaction

摘要：Background/Objectives: Docetaxel is a potent anti-cancer agent capable of treating various types of cancer. However, it often induces a range of adverse reactions when used with its standard solubilizer, Tween-80, necessitating allergy prophylaxis with dexamethasone prior to administration. To mitigate the risk of allergic reactions, with nanomicelles garnering significant interest due to their enhanced solubility and thermodynamic stability. Methods: In this research, a mPEG-PLA-Lys(Fmoc) micellar carrier with m = 45 and n = 10 was engineered to encapsulate docetaxel, and its self-assembly into micelles was investigated. Additionally, allergic reaction studies were conducted on animals. Results: The findings indicated that the formulation did not cause hemolysis, vascular, or muscle irritation in rabbits, nor did it elicit an allergic response in guinea pigs. Conclusions: These results suggest that nanomicelle-encapsulated docetaxel can diminish the allergic reactions associated with docetaxel injections, offering a novel approach to enhance the therapeutic utility of this outstanding anti-cancer drug.